Vivaldi Biosciences

Developing flu vaccines with superior efficacy and greater protection against emerging strains of flu viruses.


An early-stage investment by the Partnership Fund to support the commercialization of technology spun out of Mount Sinai Health System.


Developing live attenuated influenza vaccines  to address the need for a rapid and effective response to emerging pandemics with vaccines that are easily administered, safe, effective and protect the most vulnerable populations—seniors and young children.

Visit site